Floatz logo

Car-Bcma T Cells

B Cell Leukemia

Kang YUCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the B Cell Leukemia cohort.

Asset / SponsorPhaseRating
CD19-CAR-T2 Cells
Nanfang Hospital, Southern Medical University
Phase 2B
Autologous 3Rd Generation Cd19-Targeting Car T Cells
Uppsala University
Phase 1/2CCC
Cart-19 And 20 Cells
University of Pennsylvania
Phase 1/2CCC
Tisagenlecleucel
iCell Gene Therapeutics
Phase 1CCC
cd22 car-transduced t cells
Chinese PLA General Hospital
Phase 1/2CCC

View all 23 →

Same molecule, other indications

Car-Bcma T Cells is also rated in:

plasma cell myelomaDormant
CCC
Indicative ·
54 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
D
Indicative ·
30 / 100
View asset →
exocrine pancreatic carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →